J Pathol Transl Med.  2023 Nov;57(6):337-340. 10.4132/jptm.2023.09.22.

What’s new in dermatopathology 2023: WHO 5th edition updates

• Ho J
• Collie CJ

• KMID: 2547932
• DOI: http://doi.org/10.4132/jptm.2023.09.22

Abstract

The 5th edition WHO Classification of Skin Tumors (2022) has introduced changes to nomenclature and diagnostics. Important differences are discussed below. Changes in each category of skin tumor have been detailed, with particular emphasis on meaningful advances in our understanding of the molecular pathogenesis of the skin’s diverse tumor landscape.

Figure

• 

  Fig. 1. Keratoacanthoma. This crateriform squamous cell carcinoma variant possesses self-resolving potential. Thick glassy epithelium (yellow dot) may regress via thinner basophilic epithelium (green dot) as shown in the image.

• 

  Fig. 2. Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma of skin). The tumor demonstrates round blue cells with a characteristic finely dispersed “salt and pepper” chromatin pattern. Both Merkel cell polyomavirus associated and non-associated cases exist.

• 

  Fig. 3. Wnt-activated deep penetrating/plexiform melanocytoma. This tumor lacks maturation with descent, displays nested/plexiform melanocytes with visible nucleoli, some nuclear pleomorphism, nuclear pseudoinclusions, and melanophages. Expresses nuclear β-catenin and LEF1.

• 

  Fig. 4. Onychomatricoma. Note typical papillomatous projections of matrical-type epithelium with deep V-shaped invaginations. Subjacent spindle cell proliferation expresses CD34.

Reference

References

1. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014; 9:239–71.

2. Raghavan SS, Saleem A, Wang JY, Rieger KE, Brown RA, Novoa RA. Diagnostic utility of LEF1 immunohistochemistry in differentiating deep penetrating nevi from histologic mimics. Am J Surg Pathol. 2020; 44:1413–8.

3. de la Fouchardiere A, Pissaloux D, Tirode F, Karanian M, Fletcher CDM, Hanna J. Clear cell tumor with melanocytic differentiation and ACTIN-MITF translocation: report of 7 cases of a novel entity. Am J Surg Pathol. 2021; 45:962–8.

4. de la Fouchardiere A, Pissaloux D, Tirode F, Hanna J. Clear cell tumor with melanocytic differentiation and MITF-CREM translocation: a novel entity similar to clear cell sarcoma. Virchows Arch. 2021; 479:841–6.

5. Sekine S, Kiyono T, Ryo E, et al. Recurrent YAP1- MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest. 2019; 129:3827–32.

6. Nishimura Y, Ryo E, Yamazaki N, Yatabe Y, Mori T. Cutaneous primary NUT carcinoma With BRD3- NUTM1 Fusion. Am J Surg Pathol. 2021; 45:1582–4.

7. Héritier S, Emile JF, Barkaoui MA, et al. BRAF mu- tation correlates with high-risk langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016; 34:3023–30.

8. Bontoux C, Baroudjian B, Le Maignan C, et al. CRTC1-TRIM11 fusion in a case of metastatic clear cell sarcoma: are CRTC1-TRIM11 fusion-bearing tumors melanocytomas or clear cell sarcomas? Am J Surg Pathol. 2019; 43:861–3.

9. Yang L, Yin Z, Wei J, et al. Cutaneous melanocytic tumour with CRTC1::TRIM11 fusion in a case with recurrent local lymph node and distant pulmonary metastases at early stage: aggressive rather than indolent? Histopathology. 2023; 82:368–71.

10. Puls F, Carter JM, Pillay N, et al. Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor. Mod Pathol. 2022; 35:767–76.